Richard Blair, MD
Nephrology · Greenville, NCNPI 1386646628
Payments from drug & device makers
What this record shows
This record is dominated by other: $8,194 of the $13,262 with a category attached, or 61.8%. Angiodynamics, Inc. accounts for 61.8% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2024 at $8,163 and has fallen 91.9% since, to $659 in 2025. Among nephrology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $70.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$8K
- Medtronic$1K
- Amgen$629
- Otsuka America Pharmaceutical, Inc.$555
- Nxstage Medical, Inc.$392
- GSK$388
- plus $2K from 24 others
What the payments were for
- Consulting fees$2702%
- Speaking & faculty fees$2392%
- Travel & lodging$9437%
- Food & beverage$3,49226%
- Education$1231%
- Other$8,19462%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $8,194 |
| Medtronic | 8 | $1,113 |
| Amgen(2 entities) | 32 | $629 |
| Otsuka America Pharmaceutical, Inc. | 32 | $555 |
| Nxstage Medical, Inc. | 5 | $392 |
| GSK | 11 | $388 |
| Vifor Pharma, Inc. | 9 | $320 |
| AstraZeneca(2 entities) | 14 | $250 |
| Fresenius USA Marketing, Inc. | 8 | $199 |
| Cumberland Pharmaceuticals, Inc. | 2 | $144 |
| OPKO Pharmaceuticals, LLC | 9 | $138 |
| Bard Peripheral Vascular, Inc. | 7 | $127 |
| Aurinia Pharma U.S., Inc. | 7 | $98 |
| Bayer | 5 | $87 |
| Philips North America LLC | 5 | $83 |
| Novartis | 3 | $69 |
| Travere Therapeutics, Inc. | 3 | $63 |
| Novo Nordisk | 3 | $53 |
| Merck | 3 | $42 |
| Mallinckrodt Hospital Products Inc. | 3 | $41 |
| Ardelyx, Inc. | 2 | $40 |
| BD | 1 | $39 |
| Akebia Therapeutics Inc | 3 | $36 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Boehringer Ingelheim | 2 | $33 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $15 |
| Veloxis Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,262 in reported general payments places this provider in the 90th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 56 | $80 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Greenville
- William KendrickGreenville$125K
- Anthony ProvenzanoGreenville$11K
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
- James McCabeWilmington$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.